References
- 1Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011; 377:1198-209.10.1016/S0140-6736(10)62001-621459211JoshiDO’GradyJDieterichDGazzardBAgarwalKIncreasing burden of liver disease in patients with HIV infectionLancet20113771198209
- 2Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011;8:12-22.10.1007/s11904-010-0071-321221855OperskalskiEAKovacsAHIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologiesCurr HIV/AIDS Rep201181222
- 3Mallet V, Vallet-Pichard A, Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int. 2011;1:135-9.MalletVVallet-PichardAPolSThe impact of human immunodeficiency virus on viral hepatitisLiver Int201111359
- 4Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS. 2003; 17:2191-9.10.1097/00002030-200310170-0000714523276LawWPDoreGJDuncombeCJMahanontharitABoydMARuxrungthamKet alRisk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001AIDS20031721919
- 5den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000; 14:2895-902.10.1097/00002030-200012220-0001111153671denBrinker MWitFWWertheim-vanDillen PMJurriaansSWeelJvanLeeuwen Ret alHepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infectionAIDS2000142895902
- 6Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/ hepatitis C co-infected cohorts. PLoS One. 2009; 4: e4517.10.1371/journal.pone.0004517MoodieEEPantPai NKleinMBIs antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/ hepatitis C co-infected cohortsPLoS One20094e4517
- 7Puoti M, Nasta P, Gatti F, Matti A, Prestini K, Biasi L, et al. HIV-related liver disease: ARV drags, coinfection, and other risk factors. J Int Assoc Physicians AIDS Care (Chic). 2009; 8:30-42.10.1177/1545109708330906PuotiMNastaPGattiFMattiAPrestiniKBiasiLet alHIV-related liver disease: ARV drags, coinfection, and other risk factorsJ Int Assoc Physicians AIDS Care (Chic)200983042
- 8Merchante N, Merino E, Lopez-Aldeguer J, Jover F, Delgado-Fernandez M, Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis. 2013; 56:143-50.2295543810.1093/cid/cis777MerchanteNMerinoELopez-AldeguerJJoverFDelgado-FernandezMGalindoMJet alIncreasing incidence of hepatocellular carcinoma in HIV-infected patients in SpainClin Infect Dis20135614350
- 9Nunnari G, Berretta M, Pinzone MR, Di Rosa M, Berretta S, Cunsolo G, et al. Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci. 2012; 16:1257-70.23047511NunnariGBerrettaMPinzoneMRDiRosa MBerrettaSCunsoloGet alHepatocellular carcinoma in HIV positive patientsEur Rev Med Pharmacol Sci201216125770
- 10MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol. 2008; 14:1657-63.10.3748/wjg.14.165718350596MacDonaldDCNelsonMBowerMPowlesTHepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART eraWorld J Gastroenterol200814165763
- 11Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM, Database TAHO. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol. 2007; 22:1510-8.10.1111/j.1440-1746.2007.05062.x17645479ZhouJDoreGJZhangFLimPLChenYMDatabaseTAHOHepatitis B and C virus coinfection in The TREAT Asia HIV Observational DatabaseJ Gastroenterol Hepatol20072215108
- 12Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J Med Assoc Thai. 2004; 87:1349-54.15825712SungkanuparphSVibhagoolAManosuthiWKiertiburanakulSAtamasirikulKAumkhyanAet alPrevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based studyJ Med Assoc Thai200487134954
- 13Sungkanuparph S, Wongprasit P, Manosuthi W, Atamasirikul K. Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting. Southeast Asian J Trop Med Public Health. 2008; 39: 863-6.SungkanuparphSWongprasitPManosuthiWAtamasirikulKCompliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited settingSoutheast Asian J Trop Med Public Health2008398636
- 14Phanuphak P. Antiretroviral treatment in resource-poor settings: what can we learn from the existing programmes in Thailand?. AIDS. 2004; 18 Suppl 3: S33-8.15322482PhanuphakPAntiretroviral treatment in resource-poor settings: what can we learn from the existing programmes in Thailand?AIDS200418 Suppl 3S338
- 15Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, Fox K, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr. 2009; 50:506-12.10.1097/QAI.0b013e318196760219223784ChasombatSMcConnellMSSiangphoeUYuktanontPJirawattanapisalTFoxKet alNational expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomesJ Acquir Immune Defic Syndr20095050612
- 16Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008; 91:1925-35.19133532SungkanuparphSAnekthananonTHiransuthikulNBowonwatanuwongCSupparatpinyoKMootsikapunPet alGuidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008J Med Assoc Thai200891192535
- 17World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision. Geneva: World Health Organization; 2010. 165 p.World Health OrganizationAntiretroviral Therapy for HIV Infection in Adults and AdolescentsRecommendations for a Public Health Approach 2010 RevisionGeneva: World Health Organization;2010165
- 18Sungkanuparpha S, Techasathitb W, Utaipiboonc C, Chasombatd S, Bhakeecheepe S, Leechawengwongsf M, Ruxrangthamg K, Phanuphakg P. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed. 2010; 4: 515-28.SungkanuparphaSTechasathitbWUtaipibooncCChasombatdSBhakeecheepeSLeechawengwongsfMRuxrangthamgKPhanuphakgPThai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010Asian Biomed2010451528
- 19Tsuchiya N, Pathipvanich P, Rojanawiwat A, Wichukchinda N, Koga I, Koga M, et al. Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in Northern Thailand. Epidemiol Infect. 2013; 141:1840-8.2311426210.1017/S0950268812002397TsuchiyaNPathipvanichPRojanawiwatAWichukchindaNKogaIKogaMet alChronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in Northern ThailandEpidemiol Infect201314118408
- 20Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol. 2010; 8: 1002-12.10.1016/j.cgh.2010.08.02420851211PriceJCThioCLLiver disease in the HIV-infected individualClin Gastroenterol Hepatol20108100212
- 21Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013; 8:e83892.10.1371/journal.pone.008389224367617LomtadzeNKupreishviliLSalakaiaAVashakidzeSSharvadzeLKempkerRRet alHepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosisPLoS One20138e83892
- 22Lo Re V, 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, et al. Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol. 2008; 43:32-6.10.1016/j.jcv.2008.03.03018486540LoRe V
3rd WertheimerBLocalioARKostmanJRDockterJLinnenJMet alIncidence of transaminitis among HIV-infected patients with occult hepatitis BJ Clin Virol200843326 - 23Wondimeneh Y, Alem M, Asfaw F, Belyhun Y. HBV and HCV seroprevalence and their correlation with CD4 cells and liver enzymes among HIV positive individuals at University of Gondar Teaching Hospital, Northwest Ethiopia. Virol J. 2013; 10:171.10.1186/1743-422X-10-17123721493WondimenehYAlemMAsfawFBelyhunYHBV and HCV seroprevalence and their correlation with CD4 cells and liver enzymes among HIV positive individuals at University of Gondar Teaching Hospital, Northwest EthiopiaVirol J201310171
- 24Servin-Abad L, Molina E, Baracco G, Arosemena L, Regev A, Jeffers L, et al. Liver enzymes elevation after HAART in HIV-HCV co-infection. J Viral Hepat. 2005; 12:429-34.10.1111/j.1365-2893.2005.00617.x15985015Servin-AbadLMolinaEBaraccoGArosemenaLRegevAJeffersLet alLiver enzymes elevation after HAART in HIV-HCV co-infectionJ Viral Hepat20051242934
- 25Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, et al. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Pub Health. 2010; 10:105.10.1186/1471-2458-10-105MbouguaJBLaurentCKouanfackCBourgeoisACiaffiLCalmyAet alHepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in CameroonBMC Pub Health201010105
- 26Yang R, Gui X, Xiong Y, Gao S, Zhang Y, Deng L, et al. Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese. Infection. 2011; 39:427-31.10.1007/s15010-011-0145-1YangRGuiXXiongYGaoSZhangYDengLet alRisk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han ChineseInfection20113942731
- 27Sterling RK, Contos MJ, Smith PG, Stravitz RT, Luketic VA, Fuchs M, et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology. 2008; 47:1118-27.10.1002/hep.2213418366118SterlingRKContosMJSmithPGStravitzRTLuketicVAFuchsMet alSteatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfectionHepatology200847111827
- 28Machado MV, Oliveira AG Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology. 2010; 52:71-8.10.1002/hep.2361920578130MachadoMVOliveiraAG Cortez-Pinto HHepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factorsHepatology201052718
- 29Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008; 22: 1979-91.1878446110.1097/QAD.0b013e32830e6d51TheinHHYiQDoreGJKrahnMDNatural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysisAIDS200822197991
- 30Chauvel O, Lacombe K, Bonnard ?, Lascoux-Combe C, Molina JM, Miailhes P, et al. Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy. Antivir Ther. 2007; 12:1115-26.18018770ChauvelOLacombeKBonnard?Lascoux-CombeCMolinaJMMiailhesPet alRisk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapyAntivir Ther200712111526
- 31Mulu W, Gidey B, Chernet A, Alem G, Abera B. Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia. Ethiop J Health Sci. 2013; 23:217-26.24307821MuluWGideyBChernetAAlemGAberaBHepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, EthiopiaEthiop J Health Sci20132321726
- 32Anigilaje EA, Olutola A. Prevalence and clinical and immunoviralogical profile of human immunodeficiency virus-hepatitis B coinfection among children in an antiretroviral therapy programme in Benue State, Nigeria. ISRN Pediatr. 2013; 2013:932697.AnigilajeEAOlutolaAPrevalence and clinical and immunoviralogical profile of human immunodeficiency virus-hepatitis B coinfection among children in an antiretroviral therapy programme in Benue State, NigeriaISRN Pediatr20132013932697
- 33Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis. 2009; 49:1268-73.10.1086/60567519772386IdokoJMeloniSMuazuMNimzingLBadungBHawkinsCet alImpact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in NigeriaClin Infect Dis200949126873
- 34Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012; 104:1599-611.10.1093/jnci/djs37223073549WenCPLinJYangYCTsaiMKTsaoCKEtzelCet alHepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminasesJ Natl Cancer Inst20121041599611
- 35Chalermchai T, Hiransuthikul N, Tangkijvanich P, Pinyakorn S, Avihingsanon A, Ananworanich J. Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection. AIDS Res Ther. 2013; 10:21.10.1186/1742-6405-10-21ChalermchaiTHiransuthikulNTangkijvanichPPinyakornSAvihingsanonAAnanworanichJRisk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infectionAIDS Res Ther20131021